Key facts

  • A world leader within diabetes and haemophilia
  • Sales totalled DKK 88.806 million in 2014
  • In 2014 total insulin market share of 47% and modern insulin market share 46%, measured by volume (Source IMS)
  • 40.957 full time employees at the end of 2014
  • Focus on core areas with large unmet medical needs: Diabetes care, haemophilia, growth hormone disorders and other biopharmaceuticals
  • Strong global commercial and manufacturing setup
  • Listed on Nasdaq Copenhagen and New York Stock Exchange